Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03144687 · ClinicalTrials.gov registry record · Phase 2
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03144687 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 23 participants.
The verdict
NCT03144687, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in participants with myelofibrosis (MF).
Interventions
- DRUG Ruxolitinib
- DRUG Itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03144687
The ClinicalTrials.gov registry entry for NCT03144687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT03144687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03144687 about?
NCT03144687 is a clinical study titled "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis". The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in participants with myelofibrosis (MF).
What is the current status of trial NCT03144687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-01-26. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT03144687?
The interventions under investigation include: Ruxolitinib (DRUG), Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03144687?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.